CORE--BIOSAMPLE REPOSITORY

核心--BIOSAMPLE存储库

基本信息

批准号：
7881792
负责人：
Robert C Young
金额：
$ 17.41万
依托单位：
FOX CHASE CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7881792
关键词：
Access to Information Accreditation Address Affect Aliquot Behavioral Blood Blood Banks Blood Platelets Blood specimen Breast Cell membrane Cells Clinical Clinical Research Clinical Trials Code Collaborations Comprehensive Cancer Center Consent Core Facility DNA DNA Methylation Data Databases Date of birth Development Developmental Therapeutics Program Diagnostic Neoplasm Staging Doctor of Philosophy Drug toxicity Early Diagnosis Epigenetic Process Erythrocytes Family Family Cancer History Fox Chase Cancer Center Foxes Funding Future Gene Expression Genetic Genetic Predisposition to Disease Genotype Goals Health Health Insurance Portability and Accountability Act Histology Hormones Housing Human Human Genetics Immune response Individual Informed Consent Intervention Knowledge Leukocytes Liquid substance Lung Lymphocyte Lymphocyte Subset Malignant Neoplasms Malignant neoplasm of ovary Malignant neoplasm of prostate Medical Medical Records Membrane Proteins Molecular Profiling Names Nature Outcome Ovarian Participant Patients Pattern Peer Review Pharmaceutical Preparations Pharmacogenomics Plasma Privacy Process Proteomics Psychological Stress Quality Control Questionnaires Recording of previous events Records Research Research Ethics Committees Research Infrastructure Research Personnel Research Project Grants Research Support Resources Risk Assessment Role Sampling Screening for cancer Series Serum Services Site Visit Social Security Number Specimen Spottings Staging Structure Supervision Telephone Therapeutic Monoclonal Antibodies Time Tissues Translational Research Tube Tumor Tissue Vial device Whole Blood cancer diagnosis cancer genetics cancer prevention cancer risk cohort kindred lifestyle factors lymphoblastoid cell line malignant breast neoplasm patient privacy programs ranpirnase repository response selective expression smoking cessation tumor

项目摘要

Translational research requires access to appropriately consented and well-characterized human biosamples. Therefore, the Fox Chase Cancer Center (FCCC) established the Biosample Repository Core Facility (BRCF) in 1999/2000 to support this research. The BRCF is a CAP accreditation and CLIA-approved Facility that has two major functions: 1) BRCF staff identifies participants, administers informed consent for blood and tissue use, and collects blood samples and information on personal and family histories of cancer, clinical intervention, clinical outcomes, and lifestyle factors for use in research, and 2) BRCF staff processes and houses human biospecimens obtained through investigator-initiated studies. The FCCC has many funded research Programs which require access to biospecimens from large cohorts of properly consented individuals affected and unaffected with cancer. Programs include: i) clinical studies to assess genetic susceptibility in cancer prone-kindreds, ii) large scale genotyping studies to identify genetic modifiers of cancer risk, iii) pharmacogenomic studies to identify drug response and drug toxicity markers, iv) hormone and immune response studies to determine the role of psychological stress and breast cancer risk, v) smoking cessation studies using genetic modifiers to assess behavioral response, vi) hormone and genotype studies to predict cancer risks, vii) identifying plasma membrane proteins that are selectively expressed in lung or prostate cancer to identify new targets for the development of additional therapeutic monoclonal antibodies, and viii) studies of early detection of cancer by genetic, epigenetic, and proteomic approaches. The BRCF provides a centralized service for accrual, consenting, processing, banking, and/or distribution of human blood samples (e.g., whole blood, plasma, serum, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA) and cancer history data to be utilized in genetic-, epigenetic-, and proteomic-related research. The BRCF currently houses more than 300,000 human biosamples and has served 28 (26 peer-reviewed funded) Fox Chase investigators across 12 Programs and the three Divisions since its inception at the time of previous Core renewal. Ninety-six percent (96%) of the BRCF's use is by peer-reviewed funded investigators.

转化研究需要获得适当同意和充分表征的信息人类生物样本。因此，福克斯蔡斯癌症中心 (FCCC) 建立了生物样本 1999/2000 年的知识库核心设施 (BRCF) 支持这项研究。 BRCF 是一个 CAP 认证和 CLIA 批准的设施，具有两个主要功能：1) BRCF 工作人员确定参与者，对血液和组织使用给予知情同意，并收集血液样本以及有关个人和家族癌症史、临床干预、临床结果和生活方式因素的信息以用于研究，以及 2) BRCF 工作人员处理和保存获得的人类生物样本通过研究者发起的研究。 FCCC 有许多资助的研究项目，这些项目需要从大量经过适当同意的患有和未患癌症的个体中获取生物样本。计划包括：i) 评估癌症易感性家族遗传易感性的临床研究，ii) 大规模基因分型研究，以确定癌症风险的遗传修饰因素，iii) 药物基因组研究，以确定药物反应和药物毒性标记物，iv) 激素和免疫反应确定心理压力和乳腺癌风险的作用的研究，v) 使用基因修饰剂评估行为反应的戒烟研究，vi) 预测癌症风险的激素和基因型研究，vii) 识别选择性的质膜蛋白在肺癌或前列腺癌中表达，以确定开发其他治疗性单克隆抗体的新靶标，以及 viii) 通过遗传、表观遗传和蛋白质组学方法进行癌症早期检测的研究。 BRCF 为人类血液样本（例如全血、血浆、血清、富血小板血浆、血小板匀浆、红细胞、白细胞、淋巴母细胞系）的应计、同意、处理、存储和/或分配提供集中服务和 DNA）和癌症历史数据可用于遗传、表观遗传和蛋白质组学相关研究。 BRCF 目前保存着超过 300,000 份人类生物样本，自上一次核心更新时成立以来，已为 12 个项目和三个部门的 28 名（26 名同行评审资助的）Fox Chase 研究人员提供服务。百分之九十六 (96%) 的 BRCF 使用是由同行评审资助的研究人员进行的。